spacer
home > epc > winter 2003 > hyperbaric oxygen therapy and diabetes
PUBLICATIONS
European Pharmaceutical Contractor

Hyperbaric Oxygen Therapy and Diabetes

Treatment and Benefits of Hyperbaric Oxygen Therapy

HBO therapy is the provision of oxygen at raised pressure. Oxygen (O2) behaves like a drug with response depending on the dose:
Air at 1 atmosphere gives a dose of 0.2 bar O2
100 per cent oxygen at 1 atmosphere gives a dose of 1 bar O2
100 per cent oxygen at 2.8 bar gives a dose of 2.8 bar O2 (that is 14 times the dose of O2 compared with air at 1 atmosphere)

Patients breathe the oxygen via a mask, hood or ventilator at pressures above 1 atmosphere (bar) and are treated in a recompression chamber, where they are accompanied by a doctor, nurse or attendant. The pressure in the chamber is raised with compressed air. The attendants will therefore breathe this air for most of the treatment duration, and at designated times they will have to breathe oxygen which lowers the risk of decompression illness.

Patients will receive between two and 40 treatments depending on the medical condition being treated. Typically patients with decompression illness or carbon monoxide poisoning may only require between one and three treatment sessions, while patients with difficult wounds may require up to 40. The pressure in the chamber is raised to between 2.4 and 2.8 bar, and each treatment will last from two to eight hours, again depending on the medical condition.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sara Hasan, Hyperbaric Nurse Consultant, Peter Dodds, Manager, Hyperbaric Medicine Unit, and Phil Catling, Business Group Manager, Electro-Optic Systems at QinetiQ

Sara Hasan trained at St Mary's Hospital in Paddington. She has over 20 years' nursing experience, mostly in critical care, and joined the Hyperbaric Medicine Unit at Haslar in 1997 where she is a Hyperbaric Nurse Consultant.

Peter Dodds is responsible for the day-to-day running of the Hyperbaric Medicine Unit. His technical experience in this area goes back to 1980 when he first became involved in experimental diving programmes.

Phil Catling has over 30 years' experience in human factors and avionics systems R&D. He manages QinetiQ's diabetic retinopathy programme and is also active in progressing other health-related activities.

spacer
Sara Hasan
spacer
spacer
spacer
Peter Dodds
spacer
spacer
spacer
Phil Catling
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement